IRLAB A — IRLAB Therapeutics AB Balance Sheet
0.000.00%
- SEK197.06m
- SEK116.73m
- SEK94.63m
Annual balance sheet for IRLAB Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 277 | 402 | 253 | 111 | 66.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.71 | 10.7 | 9.83 | 9.17 | 10.4 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 284 | 421 | 269 | 124 | 79.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.32 | 8.35 | 8.01 | 6.67 | 9.79 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 370 | 472 | 324 | 177 | 136 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 20.9 | 69.4 | 32.3 | 36.7 | 100 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 22.2 | 73 | 32.7 | 61.4 | 104 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 348 | 399 | 291 | 116 | 32.6 |
| Total Liabilities & Shareholders' Equity | 370 | 472 | 324 | 177 | 136 |
| Total Common Shares Outstanding |